Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of UB-221 in Chronic Spontaneous Urticaria
NCT03632291Phase 1Completed
- Sponsor
- United BioPharma
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ub-221 in chronic spontaneous urticaria (CSU) (5 arms), sponsored by United BioPharma. Primary endpoint: Adverse event incidence at 15 days. Started Apr 2019; status: completed.
02
Drugs
ub-221
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03632291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632291.